The pitchforks and torches are out in force on Mylan's Facebook page. What I hope cooler discussion promotes on this medium is a longer term approach to the broader concern of two items (1) competition leading to robust choices in autoinjectors in the US market that reflect successful products offered for years in the UK, Sweden; (2) FARE must purge its pharmaceutical conflicts of interest by selling off its vested interest by way of Aimmune stock, and invite external, independent, and fully transparent audit of its direct and indirect financial relationship with Mylan.
SJP broke up with Mylan! Carrie knows what's up!
We are not a herd to be farmed, managed, then fed to the makers of medicines. It's too much to expect of members whose reasonable expectations of annual dues contributes to their true best interest. Last word is a lowered EpiPen price is not a final answer, only a short term solution for some. We need our independence back in advocacy free of the market forces of pharm investors, and autoinjector choices as well as technological ADVANCES. Patents in theory are to serve the public and reward innovation. Limited 'deadweight loss' is granted by the government to allow the public to trust a branded good. This has mutated into market dominance stifling innovation and entry by competitors in life or death stakes.
Cheers, ladies. Keep on rockin'.